Figures & data
Figure 1 Effect of miR-138 on the histological changes of skin ulcer model in rats. (A) The expression of miR-138 mRNA in different groups. (B) The morphological changes of foot ulceration in different groups (×200). **p < 0.01 against Control group; ##p < 0.01 against DFU group; ^^p < 0.01 against NC group; &&p < 0.01 against miR-138 inhibitor group; $$p < 0.01 against IGF-1 group.
![Figure 1 Effect of miR-138 on the histological changes of skin ulcer model in rats. (A) The expression of miR-138 mRNA in different groups. (B) The morphological changes of foot ulceration in different groups (×200). **p < 0.01 against Control group; ##p < 0.01 against DFU group; ^^p < 0.01 against NC group; &&p < 0.01 against miR-138 inhibitor group; $$p < 0.01 against IGF-1 group.](/cms/asset/e29dd9f9-9fa6-454e-b490-a7d1aefefd5c/dmso_a_359759_f0001_c.jpg)
Figure 2 Down-regulation of miR-138 alleviates inflammatory response (A) and wound healing ((B), ×200) in DFU rats. *p < 0.05, **p < 0.01 against Control group; #p < 0.05, ##p < 0.01 against DFU group; ^^p < 0.01 against NC group; &p < 0.05, &&p < 0.01 against miR-138 inhibitor group; $p < 0.05, $$p < 0.01 against IGF-1 group.
![Figure 2 Down-regulation of miR-138 alleviates inflammatory response (A) and wound healing ((B), ×200) in DFU rats. *p < 0.05, **p < 0.01 against Control group; #p < 0.05, ##p < 0.01 against DFU group; ^^p < 0.01 against NC group; &p < 0.05, &&p < 0.01 against miR-138 inhibitor group; $p < 0.05, $$p < 0.01 against IGF-1 group.](/cms/asset/ca2a2cfc-f1bb-49e0-bcb0-74317e782b43/dmso_a_359759_f0002_c.jpg)
Figure 3 Down-regulation of miR-138 improves blood vessel formation in DFU rats. (A) CD34 immunohistochemical staining was used to evaluate vessel density (×200). (B) Western blot was used to detect the expression of blood vessel formation and PI3K/AKT pathway related proteins. *p < 0.05, **p < 0.01 against Control group; #p < 0.05, ##p < 0.01 against DFU group; ^^p < 0.01 against NC group; &p < 0.05, &&p < 0.01 against miR-138 inhibitor group; $p < 0.05, $$p < 0.01 against IGF-1 group.
![Figure 3 Down-regulation of miR-138 improves blood vessel formation in DFU rats. (A) CD34 immunohistochemical staining was used to evaluate vessel density (×200). (B) Western blot was used to detect the expression of blood vessel formation and PI3K/AKT pathway related proteins. *p < 0.05, **p < 0.01 against Control group; #p < 0.05, ##p < 0.01 against DFU group; ^^p < 0.01 against NC group; &p < 0.05, &&p < 0.01 against miR-138 inhibitor group; $p < 0.05, $$p < 0.01 against IGF-1 group.](/cms/asset/18ed40a9-bff5-4302-982e-e1522eb76b27/dmso_a_359759_f0003_c.jpg)
Figure 4 Effect of miR-138 on hTERT. (A) hTERT is a target gene of miR-138. (B) qRT-PCR was used to detect the mRNA expression of miR-138 and hTERT. @@p < 0.01 against miR-NC group. **p < 0.01 against Control group; ##p < 0.01 against HG group; ^p < 0.05, ^^p < 0.01 against NC group; &&p < 0.01 against miR-138 inhibitor group; $$p < 0.01 against IGF-1 group; %%p < 0.01 against inhibitor + LY group.
![Figure 4 Effect of miR-138 on hTERT. (A) hTERT is a target gene of miR-138. (B) qRT-PCR was used to detect the mRNA expression of miR-138 and hTERT. @@p < 0.01 against miR-NC group. **p < 0.01 against Control group; ##p < 0.01 against HG group; ^p < 0.05, ^^p < 0.01 against NC group; &&p < 0.01 against miR-138 inhibitor group; $$p < 0.01 against IGF-1 group; %%p < 0.01 against inhibitor + LY group.](/cms/asset/5c48f6f5-f8a2-470e-832f-3544d909fe26/dmso_a_359759_f0004_c.jpg)
Figure 5 Effect of miR-138 on the cellular bioactivity of HUVECs. (A) CCK-8 assay. (B) Tube formation assay (×200). (C) Transwell assay (×200). *p < 0.05, **p < 0.01 against Control group; #p < 0.05, ##p < 0.01 against HG group; ^p < 0.05, ^^p < 0.01 against NC group; &p < 0.05, &&p < 0.01 against miR-138 inhibitor group; $p < 0.05, $$p < 0.01 against IGF-1 group.
![Figure 5 Effect of miR-138 on the cellular bioactivity of HUVECs. (A) CCK-8 assay. (B) Tube formation assay (×200). (C) Transwell assay (×200). *p < 0.05, **p < 0.01 against Control group; #p < 0.05, ##p < 0.01 against HG group; ^p < 0.05, ^^p < 0.01 against NC group; &p < 0.05, &&p < 0.01 against miR-138 inhibitor group; $p < 0.05, $$p < 0.01 against IGF-1 group.](/cms/asset/f44b1567-ce81-4695-b2aa-2f250e26ec13/dmso_a_359759_f0005_c.jpg)
Figure 6 Effect of miR-138 on the content of inflammation (A) and PI3K/AKT pathway (B) related factors in HUVECs. **p < 0.01 against Control group; #p < 0.05, ##p < 0.01 against HG group; ^p < 0.05, ^^p < 0.01 against NC group; &p < 0.05, &&p < 0.01 against miR-138 inhibitor group; $p < 0.05, $$p < 0.01 against IGF-1 group, %%p < 0.01 against inhibitor + LY group.
![Figure 6 Effect of miR-138 on the content of inflammation (A) and PI3K/AKT pathway (B) related factors in HUVECs. **p < 0.01 against Control group; #p < 0.05, ##p < 0.01 against HG group; ^p < 0.05, ^^p < 0.01 against NC group; &p < 0.05, &&p < 0.01 against miR-138 inhibitor group; $p < 0.05, $$p < 0.01 against IGF-1 group, %%p < 0.01 against inhibitor + LY group.](/cms/asset/1473087f-4e82-4550-afe1-599842083d55/dmso_a_359759_f0006_c.jpg)